International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gagliardini Roberta, Tavelli Alessandro, Mazzotta Valentina, Raccagni Angelo Roberto, Bana Nicholas Brian, Squillace Nicola, Muccini Camilla, Giacomelli Andrea, Saracino Annalisa, Marchetti Giulia, Monforte Antonella d'Arminio, Antinori Andrea, Icona Foundation Study Group—Icona Cohort
Аннотация
OBJECTIVES: The aim of this study was to describe virological outcomes in people with HIV (PWH) after discontinuation of long-acting (LA) cabotegravir (CAB) plus rilpivirine (RPV).
METHODS: All PWH enrolled in the Icona Cohort who discontinued CAB/RPV LA and had at least one follow-up after discontinuation were included.
RESULTS: A total of 84 out of 805 (10.4%) PWH discontinued CAB/RPV, mainly due to toxicity or adverse events (67.9%). Most individuals (72.6%) returned to the same oral antiretroviral regimen used prior LA therapy. The 12-month cumulative probability of discontinuing oral ART after CAB/RPV was 19.9% (95% confidence interval [CI] 11.9-32.2%). After switching back to oral ART all individuals except one maintained or achieved HIV RNA levels below 50 copies/mL.
CONCLUSION: These findings suggest that PWH who discontinue LA CAB/RPV and resume oral ART maintain or achieve high rates of virologic suppression.
METHODS: All PWH enrolled in the Icona Cohort who discontinued CAB/RPV LA and had at least one follow-up after discontinuation were included.
RESULTS: A total of 84 out of 805 (10.4%) PWH discontinued CAB/RPV, mainly due to toxicity or adverse events (67.9%). Most individuals (72.6%) returned to the same oral antiretroviral regimen used prior LA therapy. The 12-month cumulative probability of discontinuing oral ART after CAB/RPV was 19.9% (95% confidence interval [CI] 11.9-32.2%). After switching back to oral ART all individuals except one maintained or achieved HIV RNA levels below 50 copies/mL.
CONCLUSION: These findings suggest that PWH who discontinue LA CAB/RPV and resume oral ART maintain or achieve high rates of virologic suppression.